April 23 (Reuters) – Sanofi SA:
*PHASE III LUNA 3 STUDY OF RILZABRUTINIB FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA REACHED ITS PRIMARY END END CRITERION
*PIVOTAL DATA FROM THE FIRST PHASE III STUDY OF A BTKI IN IMMUNE THROMBOCYTOPENIA (IPT) SHOWS THAT RILZABRUTINIB HAS THE POTENTIAL TO PROVIDE SIGNIFICANT CLINICAL BENEFIT TO PATIENTS WITH ITP
* REGULATORY SUBMISSIONS EXPECTED IN THE UNITED STATES AND EUROPEAN UNION BY THE END OF THE YEAR Original text on Eikon For more details, click (Editorial from Gdansk)
©2024 Thomson Reuters, all rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. “Reuters” and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.